Abstract
Tianfeng Huang
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Atopic dermatitis
10.1016/s0140-6736(20)31286-1 · 2020
Multiple roles for cytokines in atopic dermatitis: from pathogenic mediators to endotype-specific biomarkers to therapeutic targets
10.3390/ijms23052684 · 2022
Atopic dermatitis: an expanding therapeutic pipeline for a complex disease
10.1038/s41573-021-00266-6 · 2021
Air pollution and atopic dermatitis, from molecular mechanisms to population-level evidence: a review
10.3390/ijerph20032526 · 2023
Impact of air pollution on atopic dermatitis: a comprehensive review
10.1007/s12016-022-08957-7 · 2023
The impact of air pollution on atopic dermatitis
10.1007/s11882-023-01095-w · 2023
The relationship between outdoor air pollutants and atopic dermatitis of adults: a systematic review and meta-analysis
10.12932/ap-060922-1448 · 2023
Particulate matter causes skin barrier dysfunction
10.1172/jci.insight.145185 · 2021
Exposure to volatile organic compounds may contribute to atopic dermatitis in adults
10.3390/biomedicines12071419 · 2024
A network toxicology approach for mechanistic modelling of nanomaterial hazard and adverse outcomes
10.1002/advs.202400389 · 2024
Progress in toxicogenomics to protect human health
10.1038/s41576-024-00767-1 · 2024
Increased expression of aquaporin 3 in atopic eczema
10.1111/j.1398-9995.2006.01151.x · 2006
Exposure of keratinocytes to candida albicans in the context of atopic milieu induces changes in the surface glycosylation pattern of small extracellular vesicles to enhance their propensity to interact with inhibitory siglec receptors
10.3389/fimmu.2022.884530 · 2022
ZAG Regulates the Skin Barrier and Immunity in Atopic Dermatitis
10.1016/j.jid.2019.01.023 · 2019
Increased intracellular stress responses and decreased KLF2 in adult patients with atopic dermatitis
10.1016/j.cstres.2025.02.001 · 2025
Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities
10.1016/j.jaci.2010.12.1124 · 2011
scTenifoldKnk: An efficient virtual knockout tool for gene function predictions via single-cell gene regulatory network perturbation
10.1016/j.patter.2022.100434 · 2022
A central neural circuit for itch sensation
10.1126/science.aaf4918 · 2017
Highly accurate protein structure prediction with AlphaFold
10.1038/d41586-021-02265-4 · 2021
Open babel: an open chemical toolbox
10.1186/1758-2946-3-33 · 2011
AutoDock Vina 1
10.1021/acs.jcim.1c00203 · 2021
Climate conditions, weather changes, and air pollutants and atopic dermatitis: a meta-analysis
10.1001/jamadermatol.2025.1790 · 2025
Associations of ambient air pollution and daily outpatient visits for pediatric atopic dermatitis in Shanghai, China
10.1016/j.ecoenv.2024.117231 · 2024
Association between short-term exposure to environmental air pollution and atopic dermatitis flare in patients treated with dupilumab
10.1016/j.jdin.2023.01.018 · 2023
Decoding the air pollutant-psoriasis axis: a multi-layered systems toxicology investigation
10.1016/j.ecoenv.2025.119297 · 2025
Air pollution and skin diseases: a comprehensive evaluation of the associated mechanism
10.1016/j.ecoenv.2024.116429 · 2024
The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution via induction of the neurotrophic factor artemin
10.1038/ni.3614 · 2016
Taurine supplementation alleviates asthma airway inflammation aggravated by HOCl exposure
10.1016/j.jhazmat.2025.137796 · 2025
Multi-omic integration reveals alterations in nasal mucosal biology that mediate air pollutant effects on allergic rhinitis
10.1111/all.16174 · 2024
Macrophage-derived chemokine
10.1016/s0002-9440(10)64077-1 · 2001
Serum macrophage-derived chemokine
10.1046/j.1365-2249.2002.01727.x · 2002
Both Th2 and Th1 chemokines
10.1016/j.jdermsci.2004.01.001 · 2004
Macrophage-derived chemokine
10.1016/j.jdermsci.2006.08.004 · 2006
Two phase 3 trials of dupilumab versus placebo in atopic dermatitis
10.1056/nejmoa1610020 · 2016
Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials
10.1111/bjd.19574 · 2021
Improvement across dimensions of disease with lebrikizumab use in atopic dermatitis: two phase 3, randomized, double-blind, placebo-controlled monotherapy trials (advocate1 and advocate2)
10.1007/s12325-024-02974-y · 2025
PubChem 2023 update
10.1093/nar/gkac956 · 2022
ADMETlab 3
10.1093/nar/gkae236 · 2024
No additional external references are available.